[go: up one dir, main page]

PE20030760A1 - Moleculas pequenas para el tratamiento del crecimiento celular anormal - Google Patents

Moleculas pequenas para el tratamiento del crecimiento celular anormal

Info

Publication number
PE20030760A1
PE20030760A1 PE2002001190A PE2002001190A PE20030760A1 PE 20030760 A1 PE20030760 A1 PE 20030760A1 PE 2002001190 A PE2002001190 A PE 2002001190A PE 2002001190 A PE2002001190 A PE 2002001190A PE 20030760 A1 PE20030760 A1 PE 20030760A1
Authority
PE
Peru
Prior art keywords
treatment
cellular growth
erbb2
methyl
abnormal cellular
Prior art date
Application number
PE2002001190A
Other languages
English (en)
Inventor
Richard Damian Connell
James Dale Moyer
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030760A1 publication Critical patent/PE20030760A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A UN INHIBIDOR DE erbB2 DE MOLECULA PEQUENA QUE PRESENTA UN INTERVALO DE SELECTIVIDAD POR erbB2 RESPECTO A erbB1 ENTRE 50-1500 Y UNA CI50 MENOR A 50nM. EL INHIBIDOR DE erbB2 SE SELECCIONA DE N-{3-[4-(5-METIL-6-FENOXIPIRIDIN-3-ILAMINO)-QUINAZOLIN-6-IL]-PROP-2-INIL}-2-OXO-PROPIONAMIDA, (3-4{4-[3-METIL-4-(PIRIDIN-3-ILOXI)-FENILAMINO]-QUINAZOLIN-6-IL]-AMINA DEL ACIDO CICLOPROPANOCARBOXILICO, 2-METOXI-N-(3-{4-(4-(3-METOXIFENOXI)-3-METIL-FENILAMINO)-QUINAZOLIN-6-IL}-PROP-2-INIL)-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS SON UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL
PE2002001190A 2001-12-12 2002-12-10 Moleculas pequenas para el tratamiento del crecimiento celular anormal PE20030760A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
PE20030760A1 true PE20030760A1 (es) 2003-09-05

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001190A PE20030760A1 (es) 2001-12-12 2002-12-10 Moleculas pequenas para el tratamiento del crecimiento celular anormal

Country Status (29)

Country Link
US (1) US20030171386A1 (es)
EP (1) EP1465632A1 (es)
JP (1) JP4181502B2 (es)
KR (1) KR20040063948A (es)
CN (1) CN1602195A (es)
AP (1) AP2004003058A0 (es)
AR (1) AR037771A1 (es)
AU (1) AU2002339687A1 (es)
BR (1) BR0214499A (es)
CA (1) CA2469670A1 (es)
DO (1) DOP2002000545A (es)
EA (1) EA200400680A1 (es)
EC (1) ECSP045146A (es)
GT (1) GT200200273A (es)
HR (1) HRP20040529A2 (es)
HU (1) HUP0501069A2 (es)
IL (1) IL161908A0 (es)
IS (1) IS7233A (es)
MA (1) MA27154A1 (es)
MX (1) MXPA04004107A (es)
NO (1) NO20042882L (es)
OA (1) OA12734A (es)
PA (1) PA8561301A1 (es)
PE (1) PE20030760A1 (es)
PL (1) PL373848A1 (es)
TN (1) TNSN04111A1 (es)
TW (1) TW200301121A (es)
WO (1) WO2003049740A1 (es)
ZA (1) ZA200404264B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток
RU2005122659A (ru) * 2002-12-19 2006-01-20 Пфайзер Продактс Инк. (Us) Комплексы е-2-метокси-n-(3-{4-[3-метил-4-(6-метилпиридин-3-илокси) фениламино] хиназолин-6-ил} аллил) ацетамида, способ получения и применения указанных комплексов
KR20060037447A (ko) * 2003-08-18 2006-05-03 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1921864A (zh) * 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2673097A1 (en) 2006-12-12 2008-06-19 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN101939316B (zh) 2008-02-07 2013-10-02 贝林格尔.英格海姆国际有限公司 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
BR112014004762A2 (pt) 2011-08-31 2018-06-19 Genentech Inc métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
CN111643479B (zh) 2015-07-01 2023-10-27 加州理工学院 基于阳离子粘酸聚合物的递送系统
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
US20230126204A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
US20230131720A1 (en) * 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP2003504363A (ja) * 1999-07-09 2003-02-04 グラクソ グループ リミテッド プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
DE60017179T2 (de) * 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
JP4044839B2 (ja) * 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
WO2003050108A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Also Published As

Publication number Publication date
JP4181502B2 (ja) 2008-11-19
PL373848A1 (en) 2005-09-19
WO2003049740A1 (en) 2003-06-19
US20030171386A1 (en) 2003-09-11
ZA200404264B (en) 2005-08-31
CA2469670A1 (en) 2003-06-19
KR20040063948A (ko) 2004-07-14
MXPA04004107A (es) 2004-07-23
PA8561301A1 (es) 2003-12-30
IL161908A0 (en) 2005-11-20
TW200301121A (en) 2003-07-01
TNSN04111A1 (fr) 2006-06-01
CN1602195A (zh) 2005-03-30
AU2002339687A1 (en) 2003-06-23
AP2004003058A0 (en) 2004-06-30
HUP0501069A2 (en) 2006-06-28
MA27154A1 (fr) 2005-01-03
EA200400680A1 (ru) 2005-06-30
HRP20040529A2 (en) 2004-10-31
ECSP045146A (es) 2004-07-23
OA12734A (en) 2006-06-28
AR037771A1 (es) 2004-12-01
BR0214499A (pt) 2005-05-10
JP2005527486A (ja) 2005-09-15
DOP2002000545A (es) 2003-06-16
NO20042882L (no) 2004-07-07
GT200200273A (es) 2003-10-03
EP1465632A1 (en) 2004-10-13
IS7233A (is) 2004-04-26

Similar Documents

Publication Publication Date Title
PE20030760A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
PE20061088A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a
PE20091901A1 (es) Activadores de glucoquinasa
MX2007005408A (es) Compuestos de aminoquinazolinas.
UY26291A1 (es) Compuestos químicos xxii
BR122012009534B8 (pt) 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto
PE16299A1 (es) Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores
PE20211375A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
ECSP066662A (es) Preparación farmacéutica que comprende un anticuerpo contra el receptor egf
DE602004031123D1 (de) Umsetzungsprodukte von mercaptobenzothiazolen, mercaptothiazolinen und mercaptobenzimidazolen mit epoxiden als schmiermitteladditive
UA113658C2 (xx) Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання
HRP20050352B1 (hr) Piperazinilni i diazepanilni benzamidi i benztioamidi
BRPI0411750A (pt) fibra inorgánica vìtrea resistente à temperatura elevada, método para o preparo da mesma e método de isolamento de um artigo
DK1267869T3 (da) Metabotrope glutamatreceptorantagonister til behandling af tolerance og afhængighed
MA32818B1 (fr) Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
EA200600060A1 (ru) Аминосульфонилзамещенные 4-(аминометил) пиперидинбензамиды в качестве 5нт-антагонистов
RU2009134180A (ru) Нить из ароматического полиамида и способ ее получения
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
RO84816A (ro) Procedeu pentru prepararea unor 3-amino-sidnonimine substituite

Legal Events

Date Code Title Description
FC Refusal